Once weekly intravenous administration of 25 mg/kg AZD2811 resulted in a statistically significant tumor growth inhibition (TGI) of 74%, while daily 100 mg/kg venetoclax resulted in 49% TGI but failed to reach statistical significance ( Figure 5E ).
← all excerpts
Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations.
1
—
—